Abstract:
:Vascular endothelial growth factor (VEGF) and its receptors (VEGFR) have been implicated in promoting solid tumor growth and metastasis via stimulating tumor-associated angiogenesis. We recently showed that certain 'liquid' tumors such as leukemia not only produce VEGF, but also express functional VEGFR, resulting in an autocrine loop for tumor growth and propagation. A chimeric anti-VEGFR2 (or kinase insert domain-containing receptor, KDR) antibody, IMC-1C11, was shown to be able to inhibit VEGF-induced proliferation of human leukemia cells in vitro, and to prolong survival of nonobese diabetic-severe combined immune deficient (NOD-SCID) mice inoculated with human leukemia cells. Here we produced two fully human anti-KDR antibodies (IgG1), IMC-2C6 and IMC-1121, from Fab fragments originally isolated from a large antibody phage display library. These antibodies bind specifically to KDR with high affinities: 50 and 200 pM for IMC-1121 and IMC-2C6, respectively, as compared to 270 pM for IMC-1C11. Like IMC-1C11, both human antibodies block VEGF/KDR interaction with an IC(50) of approximately 1 nM, but IMC-1121 is a more potent inhibitor to VEGF-stimulated proliferation of human endothelial cells. These anti-KDR antibodies strongly inhibited VEGF-induced migration of human leukemia cells in vitro, and when administered in vivo, significantly prolonged survival of NOD-SCID mice inoculated with human leukemia cells. It is noteworthy that the mice treated with antibody of the highest affinity, IMC-1121, survived the longest period of time, followed by mice treated with IMC-2C6 and IMC-1C11. Taken together, our data suggest that anti-KDR antibodies may have broad applications in the treatment of both solid tumors and leukemia. It further underscores the efforts to identify antibodies of high affinity for enhanced antiangiogenic and antitumor activities.
journal_name
Leukemiajournal_title
Leukemiaauthors
Zhu Z,Hattori K,Zhang H,Jimenez X,Ludwig DL,Dias S,Kussie P,Koo H,Kim HJ,Lu D,Liu M,Tejada R,Friedrich M,Bohlen P,Witte L,Rafii Sdoi
10.1038/sj.leu.2402831subject
Has Abstractpub_date
2003-03-01 00:00:00pages
604-11issue
3eissn
0887-6924issn
1476-5551pii
2402831journal_volume
17pub_type
杂志文章相关文献
LEUKEMIA文献大全abstract::A patient with the M2 subtype of AML who had a 45,X,-X,t(8;21) karyotype at diagnosis was found to have the Ph chromosome in one out of 37 evaluated cells 18 months after the initial diagnosis. Interphase FISH studies utilizing a BCR-ABL dual-color probe did not detect a fusion product 4 months prior to the appearance...
journal_title:Leukemia
pub_type: 杂志文章,评审
doi:10.1038/sj.leu.2400974
更新日期:1998-04-01 00:00:00
abstract::We report here the case of a patient with refractory anemia with excess of blasts (RAEB) which evolved into RAEB in transformation. The standard Philadelphia (Ph) chromosome was found by cytogenetic study at diagnosis and during evolution. Southern blot analysis showed breakpoint cluster region (bcr) rearrangement as ...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1989-03-01 00:00:00
abstract::Arsenic has been used since ancient times as a therapeutic agent. However, until recently its use in modern medicine has been restricted to the treatment of a limited number of parasitic infections. In the early 1990s, reports from China described impressive results with arsenic trioxide in patients with de novo, rela...
journal_title:Leukemia
pub_type: 临床试验,杂志文章
doi:10.1038/sj.leu.2402599
更新日期:2002-09-01 00:00:00
abstract::The t(9;22)(q34;q11), generating the Philadelphia chromosome (Ph), is found in more than 90% of patients with chronic myeloid leukemia (CML) and in 15-30% of adults with acute lymphoblastic leukemia (ALL). Different groups have recently described the presence of large genomic deletions adjacent to the translocation br...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2402829
更新日期:2003-03-01 00:00:00
abstract::Event-free survival (EFS) at 5 years in pediatric acute lymphoblastic leukemia (ALL) is >80%. Outcome in adult ALL is still unsatisfactory, which is due to less cumulative dosing of chemotherapy and less strict adherence to timing of successive cycles. In the present phase II trial, we evaluated a pediatric regimen in...
journal_title:Leukemia
pub_type: 杂志文章,多中心研究
doi:10.1038/leu.2011.141
更新日期:2011-11-01 00:00:00
abstract::Approximately 25% of acute leukemias of the B-cell lineage demonstrate more than two rearranged immunoglobulin heavy chain genes when examined by Southern blot analysis. The origin of the extra bands was investigated by molecular cloning and sequencing of four rearranged genes from one patient's leukemic cells. All fo...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1991-08-01 00:00:00
abstract::Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-a subtype of Hodgkin lymphoma (HL)-is characterized by a low content of tumor cells, the lymphocyte predominant (LP) cells. Transformation into diffuse large B-cell lymphoma (DLBCL) occurs in about 10% of patients. We performed whole-genome mutation analysis of t...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2015.328
更新日期:2016-04-01 00:00:00
abstract::Many chemotherapeutic agents induce apoptosis in tumor cells, but killing of normal cells remains a major obstacle. Development of multidrug resistance further limits chemotherapy in cancer. Here, I show that multidrug resistance can be exploited for selective killing of multidrug-resistant cells by a combination of a...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2402127
更新日期:2001-06-01 00:00:00
abstract::Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a very rare disease that currently lacks genomic and genetic biomarkers to assist in its clinical management. We performed whole-exome sequencing (WES) of three BPDCN cases. Based on these data, we designed a resequencing approach to identify mutations in 38 sele...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2013.283
更新日期:2014-04-01 00:00:00
abstract::These ECOG trials have demonstrated that progressive increments in the intensity of post-remission therapy result in improving long-term, disease-free survival in adults with AML. The median duration of disease-free survival and long-term outcome from different post-remission therapies are summarized in Table 4. [tabl...
journal_title:Leukemia
pub_type: 临床试验,杂志文章,多中心研究,随机对照试验
doi:
更新日期:1992-01-01 00:00:00
abstract::A total of 28 children and nine adults with relapsed T-ALL were analyzed for the configuration of their T-cell receptor (TCR) and TAL1 genes at diagnosis and relapse to evaluate their stability throughout the disease course. A total of 150 clonal TCR and TAL1 gene rearrangements were identified in the 37 patients at d...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2403081
更新日期:2003-11-01 00:00:00
abstract::A new factor-independent megakaryoblastic cell line, designated SET-2, was established from the peripheral blood of a patient with leukemic transformation of essential thrombocythemia (ET). SET-2 expressed CD 4, 7, 13, 33, 34, 36, 38, 41, 61, 71, 117, 126, 130 and c-mpl. In addition, it spontaneously produced numerous...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2401608
更新日期:2000-01-01 00:00:00
abstract::Following the publication of this article, the authors noted that Patrick M. Vanderboom was inadvertently omitted from the author list. The correct author list is as follows: Sanjay Kumar, David Murray, Surendra Dasari, Paolo Milani, David Barnidge, Benjamin Madden, Patrick M. Vanderboom, Taxiarchis Kourelis, Bonnie A...
journal_title:Leukemia
pub_type: 已发布勘误
doi:10.1038/s41375-019-0405-0
更新日期:2019-04-01 00:00:00
abstract::Outcomes after unmanipulated haploidentical stem cell transplantation (Haplo) and after unrelated cord blood transplantation (UCBT) are encouraging and have become alternative options to treat patients with high-risk acute leukemia without human leukocyte antigen (HLA) matched donor. We compared outcomes after UCBT an...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2015.98
更新日期:2015-09-01 00:00:00
abstract::An amendment to this paper has been published and can be accessed via a link at the top of the paper. ...
journal_title:Leukemia
pub_type: 已发布勘误
doi:10.1038/s41375-020-0782-4
更新日期:2020-09-01 00:00:00
abstract::Peripheral arterial occlusive disease (PAOD) occurs in patients with chronic phase chronic myeloid leukemia (CML-CP) treated with tyrosine kinase inhibitors (TKIs). The risk of developing PAOD on TKI therapy is unknown and causality has not been established. Patients with CML-CP from three randomized phase III studies...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2013.69
更新日期:2013-06-01 00:00:00
abstract::Because of their substantial in vitro synergy, we conducted a dose-escalation study of cyclophosphamide (CP) added to 2-chloro-2'-deoxyadenosine (CdA) in patients with previously treated chronic lymphocytic leukemia and non-Hodgkin's lymphoma. CdA was given at a fixed dose (5.6 mg/m2/day) as a 2-h intravenous (i.v.) i...
journal_title:Leukemia
pub_type: 临床试验,杂志文章
doi:10.1038/sj.leu.2401783
更新日期:2000-06-01 00:00:00
abstract::Transformation of post-myeloproliferative neoplasms into secondary (s) AML exhibit poor clinical outcome. In addition to increased JAK-STAT and PI3K-AKT signaling, post-MPN sAML blast progenitor cells (BPCs) demonstrate increased nuclear β-catenin levels and TCF7L2 (TCF4) transcriptional activity. Knockdown of β-caten...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/s41375-018-0334-3
更新日期:2019-06-01 00:00:00
abstract::One-hundred, twenty-eight patients with Hodgkin's disease in remission or who had failed a mechlorethamine, vincristine, procarbazine and prednisone (MOPP), a doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) and/or lomustine, etoposide and prednimustine (CEP) regimens have been treated with a high-dose thera...
journal_title:Leukemia
pub_type: 临床试验,杂志文章,多中心研究
doi:
更新日期:1991-01-01 00:00:00
abstract::We reported HTLV-1 uveitis (HU) as the third distinct clinical entity associated with HTLV-1 infection. Uveitis has advantages for studying the pathogenetic mechanisms of inflammatory diseases caused by HTLV-1, since observation of the disease process is relatively easy and clinical samples from the lesion can be obta...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1997-04-01 00:00:00
abstract::The fusion transcript AML1/ETO corresponding to translocation t(8;21)(q22;q22) can be found in approximately 7-12% of childhood de novo AML. Despite the favorable prognosis, some of these patients relapse. Most of MRD studies so far were performed on adults treated not uniformly. Therefore, we analyzed the follow-up o...
journal_title:Leukemia
pub_type: 杂志文章,多中心研究
doi:10.1038/sj.leu.2402959
更新日期:2003-06-01 00:00:00
abstract::Acute leukemias of the t(4;11) (MLL-AF4 fusion gene) type frequently have high white blood counts and extramedullary disease in multiple organs. In the present study we evaluated the hypotheses that this extensive disease is the result of extramedullary survival of leukemia cells due to resistance to stress-induced ce...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2401148
更新日期:1998-10-01 00:00:00
abstract::The presence of CD19 in myelomatous plasma cells (MM-PCs) correlates with adverse prognosis in multiple myeloma (MM). Although CD19 expression is upregulated by CD81, this marker has been poorly investigated and its prognostic value in MM remains unknown. We have analyzed CD81 expression by multiparameter flow cytomet...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2012.42
更新日期:2012-08-01 00:00:00
abstract::The c-kit proto-oncogene encodes a transmembrane receptor with a tyrosine kinase internal domain. C-kit has been mapped to the W locus in the mouse, and the gene encoding the ligand has been shown to be the product of the murine SI locus. Previous genetic studies have shown that the murine W and SI loci play important...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1991-06-01 00:00:00
abstract::Inorganic arsenic trioxide (As(2)O(3)) is a highly effective treatment for acute promyelocytic leukemia (APL). However, other cancers do not respond well to this form of arsenic at clinically achievable doses. We tested a novel arsenical, S-dimethylarsino-glutathione (darinaparsin) for efficacy in various malignancies...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2008.194
更新日期:2008-10-01 00:00:00
abstract::Since graft-versus-leukemia (GVL) is the main weapon for disease eradication after reduced intensity conditioning (RIC) allogeneic SCT, the availability of sensitive and specific techniques to monitor changes in tumor load after transplant are especially helpful. These minimal residual disease techniques would allow a...
journal_title:Leukemia
pub_type: 杂志文章,评审
doi:10.1038/sj.leu.2402550
更新日期:2002-08-01 00:00:00
abstract::A novel erythroid cell line, RM10, was established from a long-term bone marrow culture of a patient with chronic myelogenous leukemia (CML). RM10 cells were positive for periodic acid Schiff (PAS), but negative for peroxidase and dual esterase. RM10 cells had la, pre B (CD10), myeloid (CD13, CD14, CD33) and erythroid...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1990-05-01 00:00:00
abstract::Human immunodeficiency virus type 1 (HIV-1) circulates in vivo as heterogeneous mixed populations (quasispecies). We analyzed the quasispecies nature of the first, second, and third hypervariable loops (V1, V2, and V3) of the gp 120 in plasma and viral isolates obtained from 19 infected individuals. Sequence analysis ...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1997-04-01 00:00:00
abstract::Most modern treatment protocols for acute lymphoblastic leukaemia (ALL) include the analysis of minimal residual disease (MRD). To ensure comparable MRD results between different MRD-polymerase chain reaction (PCR) laboratories, standardization and quality control are essential. The European Study Group on MRD detecti...
journal_title:Leukemia
pub_type: 杂志文章,多中心研究
doi:10.1038/sj.leu.2404586
更新日期:2007-04-01 00:00:00
abstract::Proto-oncogenes are thought to be involved in cellular differentiation and proliferation. Tumor necrosis factors (TNFs) are specific cytokines that have cytostatic and cytotoxic effects in vitro against a wide range of human tumor cells. We have previously demonstrated that recombinant TNFs (rTNFs) have an antiprolife...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1988-11-01 00:00:00